Présentation de l'entreprise
MDxHealth SA operates as a commercial-stage precision diagnostics entity, specializing in the provision of urologic solutions across the United States, Europe, and international markets. The company's core product offerings include Select mdx, a non-invasive urine test designed for prostate cancer detection that quantifies the expression of two mRNA cancer-related biomarkers. This business model places MDxHealth within the broader Healthcare sector, specifically functioning within the Diagnostics & Research industry, where it focuses on developing advanced testing solutions to address specific medical needs. With a market capitalization of $105.30M and annual revenue of $107.88M, the company represents a mid-sized entity within the precision medicine landscape. These valuation and revenue figures indicate that while the company has achieved sufficient scale to generate significant top-line revenue, it remains a relatively small player in the global diagnostics market, operating with limited operational breadth compared to larger pharmaceutical or technology conglomerates.
Santé financière
The company reported a trailing twelve-month revenue of $107.88M, yet it recorded a net income of -$33,519,000 and an EBITDA of -$5,200,000 during the same period. The substantial gap between the revenue figure and the negative net income reveals a cost structure characterized by significant operating expenses that exceed gross profitability, resulting in a net loss that is more than six times the magnitude of the reported EBITDA loss. Free cash flow stands at -$2,822,250, which indicates that the company is currently burning cash rather than generating liquidity, thereby limiting its immediate financial flexibility to fund organic growth without external capital injections. Gross margin is reported at 64.5%, suggesting that the cost of goods sold is relatively low compared to sales, whereas the operating margin of -17.8% and profit margin of -31.1% demonstrate that overhead costs and other operating expenses are aggressively eroding the gross profit generated by the business. The balance sheet shows a cash position of $29.03M against total debt of $86.60M, resulting in a debt-to-equity ratio that is not applicable due to the negative equity position implied by the financial structure. While the cash on hand provides a buffer, the net debt position suggests a leveraged balance sheet where liabilities significantly outweigh liquid assets. The current ratio stands at 1.08, indicating that the company holds just over $1 of current assets for every $1 of current liabilities, which suggests a tight but technically sufficient short-term liquidity position to meet its immediate obligations. Return on Equity is reported at -2440.4% and return on assets is -5.9%, metrics that reveal management has struggled to generate positive returns on the capital deployed, reflecting the challenges of scaling a loss-making diagnostic business.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is not applicable, while the forward P/E is listed at -15.77, a discrepancy that implies the market is pricing the stock based on future expectations of normalized earnings rather than historical profitability. The price-to-book ratio is -8.91, a negative figure that indicates the market values the company at a significant discount relative to its book value, often seen in distressed or turnaround situations where future potential outweighs current asset value. Alternative valuation metrics such as the price-to-sales ratio of 0.98 and an EV/EBITDA of -31.78 suggest that the market is valuing the company primarily on its revenue generation capabilities rather than its earnings power or enterprise value efficiency. The stock has traded between a 52-week high of $5.33 and a 52-week low of $1.36, providing a trading range of approximately $3.97 over the last year. Without the current price explicitly listed in the provided facts, the relative position of the current share price cannot be calculated as a percentage of the high or low, though the wide range suggests significant price volatility. The beta value is recorded as -537543.56, an anomalous figure that, if taken literally, would imply extreme volatility; however, in the context of financial data, such an outlier often indicates a data error or extreme instability in the stock's correlation to the broader market. This metric would theoretically suggest that the stock's price movements are inversely correlated with the market to a mathematically impossible degree, pointing to severe liquidity issues or trading anomalies rather than standard market behavior.
Growth & Income
Revenue growth year-over-year stands at 19.4%, while earnings growth year-over-year is not applicable due to the negative net income position. The fact that revenue is expanding while earnings growth is undefined highlights a classic growth-stage dynamic where top-line expansion is prioritized over immediate profitability, implying that the company is reinvesting its growing revenue into operations to capture market share rather than delivering profits to shareholders. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute earnings to shareholders, instead choosing to retain all available capital to fund its research and development efforts or to service its debt obligations. This strategy aligns with the company's need to maintain liquidity given its negative free cash flow and negative net income. The overall growth and income profile is defined by strong top-line expansion of nearly 20% annually, coupled with a complete absence of dividend income, positioning the investment as a pure play on the company's future operational success rather than a current income generator.